Effect of recombinant human IFNγ in the treatment of chronic pulmonary complications due to sulfur mustard intoxication. (January 2014)

• Record Type: Journal Article
• Authors: Panahi, Yunes; Ghanei, Mostafa; Vahedi, Ensieh; Ghazvini, Ali; Parvin, Shahram; Madanchi, Nima; Bagheri, Mahsa; Sahebkar, Amirhossein
• Is Part Of: Journal of immunotoxicology. Volume 11:Number 1(2014)
• Page Start: 72
• Page End: 77
• Publication Date: 2014-01
• Subjects: Immunotoxicology -- Periodicals; Poisons -- Immunology -- Periodicals; Environmental health -- Periodicals; 616.97
• DOI: 10.3109/1547691X.2013.797525
• Languages: English
• ISSNs: 1547-691X

Abstract

<abstract> <title>Abstract</title> <p>Pulmonary problems are among the most common chronic complications of sulfur mustard (SM) intoxication and adversely affect patients' quality-of-life. The present trial investigated the impact of immunotherapy with interferon (IFN)-γ on quality-of-life, respiratory symptoms, and circulating immunologic and oxidative parameters in patients suffering from chronic SM-induced complications. Patients (<italic>n</italic> = 15) were administered IFNγ (100 μg) every other day for a period of 6 months. Assessment of quality-of-life [using St. George respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) indices], the severity and frequency of respiratory symptoms, and serum levels of immunologic [including interleukin (IL)-2, IL-4, IL-6, IL-10, IFNγ, calcitonin gene related peptide (CGRP), matrix metallopeptidase (MMP)-9, and tumor necrosis factor (TNF)-α], oxidative stress [malondialdehyde (MDA) as well as total and reduced glutathione, and catalase and superoxide dismutase (SOD) activity], and fibrogenic [transforming growth factor (TGF)-β] parameters were performed at baseline and at trial end. The results indicated that IFNγ therapy is associated with improvements in SGRQ (<italic>p</italic> < 0.001) and CAT (<italic>p</italic> < 0.001) scores, decreased severity of cough (<italic>p</italic> = 0.001), dyspnea (<italic>p</italic> < 0.001), and morning dyspnea (<italic>p</italic> < 0.001), reduced frequency of sputum production (<italic>p</italic> < 0.001) and hemoptysis (<italic>p</italic> < 0.001), and elevated FEV<sub>1</sub> (<italic>p</italic> = 0.065). Serum levels of IL-4 (<italic>p</italic> < 0.001), IL-6 (<italic>p</italic> < 0.001), IL-10 (<italic>p</italic> < 0.001), CGRP (<italic>p</italic> < 0.001), MMP-9 (<italic>p</italic> = 0.001), TNFα (<italic>p</italic> < 0.001), TGFβ (<italic>p</italic> < 0.001) and MDA (<italic>p</italic> = 0.001) were decreased while those of IL-2 (<italic>p</italic> < 0.001), IFNγ (<italic>p</italic> < 0.001), and both total (<italic>p</italic> = 0.005) and reduced glutathione (<italic>p</italic> = 0.061) increased by the end of the trial. It was concluded that IFNγ has favorable effects on the quality-of-life and alleviates respiratory symptoms in patients suffering from chronic SM-induced pulmonary complications. A modulation of cytokines and oxidative stress appears responsible for the clinical efficacy of IFNγ.</p> </abstract>